Clinical Trials
40 trialsCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas
Shanghai Hengrui Pharmaceutical Co., Ltd.
ANCHOR2
Athenex, Inc.
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
Chongqing Precision Biotech Co., Ltd
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Kecellitics Biotech Company Ltd
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
Ascentage Pharma Group Inc.
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Shanghai Miracogen Inc.
SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Jiangsu HengRui Medicine Co., Ltd.
Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
Genor Biopharma Co., Ltd.
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
Shenzhen BinDeBio Ltd.
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
Shenzhen BinDeBio Ltd.
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
UWELL Biopharma
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
Oncotartis, Inc.
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
iCell Gene Therapeutics
A-319
EVIVE Biotechnology
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
Immune Cell, Inc.
A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
Shanghai AbelZeta Ltd.
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Pinze Lifetechnology Co. Ltd.
Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Centaurus Biopharma Co., Ltd.
CAR T Cells for Refractory B Cell Malignancy
Hebei Senlang Biotechnology Inc., Ltd.
Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Beijing Biohealthcare Biotechnology Co.,Ltd
A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
Sinocelltech Ltd.
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.